Fundraising FoxMoleculin Biotech
NASDAQ: MBRXHouston, US · Founded 2015 · Delaware corporation
Find your way into Moleculin Biotech
Sign up to see every warm intro you have to Moleculin Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Moleculin Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Moleculin Biotech is a pharmaceutical development company conducting late-stage clinical trials of Annamycin (naxtarubicin), a next-generation anthracycline chemotherapy designed to treat relapsed/refractory acute myeloid leukemia and other cancers with reduced cardiotoxicity compared to conventional anthracyclines. The company also maintains two additional drug portfolios targeting hard-to-treat cancers and viruses, with clinical and preclinical programs supported through academic partnerships and investigator-initiated trials.
Founders & leadership
Moleculin Biotech was founded in 2015 by Walter V. Klemp.
Funding
SEC filings, press & company announcements$15.3M disclosed across 2 rounds · 2016–2026
- $9.3MraisedAug 2026 · 2 sourcesSource ↗
▶$6MraisedMay 2016 · 129 investors · PharmaceuticalsRule 506(b)
- Louis PlothExecutive Officer
- Walter KlempExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Moleculin Biotech do?
- Moleculin Biotech is a pharmaceutical development company conducting late-stage clinical trials of Annamycin (naxtarubicin), a next-generation anthracycline chemotherapy designed to treat relapsed/refractory acute myeloid leukemia and other cancers with reduced cardiotoxicity compared to conventional anthracyclines. The company also maintains two additional drug portfolios targeting hard-to-treat cancers and viruses, with clinical and preclinical programs supported through academic partnerships and investigator-initiated trials.
- Who founded Moleculin Biotech?
- Moleculin Biotech was founded by Walter V. Klemp in 2015.
- How much funding has Moleculin Biotech raised?
- Moleculin Biotech has disclosed $15.3M raised across 2 rounds.
- Where is Moleculin Biotech headquartered?
- Moleculin Biotech is headquartered in Houston, US.